Australia: Antitrust authority approves new regulations to increase pharma transparency
The Australian Competition and Consumer Commission has given Australia’s pharmaceutical companies a timeline of two years to improve transparency in regards to the companies’ payments and sponsorships to healthcare professionals. While originally sought for a five year acceptance, Medicines Australia’s most recent Code of Conduct has been approved for two years; the new regulations are aimed at ensuring the makers of prescription drugs disclose the doctors and consumer groups they pay.
Featured News
House Votes to Pass CLARITY Act After Drama Threatened to Derail Crypto Market Structure Bill
Jul 17, 2025 by
CPI
Zillow Rejects Compass’s Antitrust Claims Amid Listing Policy Dispute
Jul 17, 2025 by
CPI
DOJ Probes ServiceNow’s $2.85B AI Merger with Moveworks
Jul 17, 2025 by
CPI
Authors Can Sue Anthropic Over Alleged AI Book Piracy, Judge Rules
Jul 17, 2025 by
CPI
Charter, Cox Request FCC Green Light for $34.5B Merger
Jul 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Surveillance Pricing
Jul 14, 2025 by
CPI
Should We Fear Personalized Pricing?
Jul 14, 2025 by
John Yun
Data and Price Competition: The Special Role of Information About Rivals’ Prices
Jul 14, 2025 by
Zach Y. Brown & Alexander MacKay
Surveillance Pricing: A Cautionary Summary of Potential Harms and Solutions
Jul 14, 2025 by
Ginger Zhe Jin, Liad Wagman & Mengyi Zhong
The Rise of Surveillance Pricing
Jul 14, 2025 by
Rebecca Kirk Fair, Alvaro Ziadi & Juan Carvajal